Prothioconazole tebuconazole suspending agent as well as preparation method and application thereof
By adjusting the formulation and process of propionazole bupropionazole suspension agent, the problem of thermal storage in the monoclinic and triclinic crystalline prothiazole original drugs in the existing technology is solved, and stability and prevention and treatment are achieved The effect of wheat gibberellia simplifies the process flow and improves grinding efficiency.
Patent Information
- Application Number
- CN202411064263.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, 40% propionazole·piperazole suspension agent is only suitable for the prothiazole original drug of triclinic crystal system. When stored heat, it will cause the system to rise and bottom, and it cannot effectively solve the monoclinic crystal system and The stability of the trispark-based prothiosacrazole.
Prothiostatazole 20%, pifoamol 20%, wet dispersant 6-10%, urea 4%, defoaming agent 0.3%, casson 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1% Formulation, through specific mixing and shear grinding processes, a stable suspension agent that adapts to different crystal forms is prepared, including shear, mixing, grinding and other steps to ensure the fluidity and stability of the formulation.
This formula significantly improves the thermal storage fluidity and storage stability of prothiotazolibuminazole suspension agent, reduces the types of additives, simplifies the process flow, improves grinding efficiency, and shows that in the prevention and treatment of wheat gibberelliasis Good safety and preventive and curative effects.
Smart Images

Figure BDA0004978908960000071
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pesticide preparation, in particular to a prothioconazole-tebuconazole suspension and a preparation method and application thereof. Background Art
[0002] "Liu Xiling, Zhang Lihui, Li Changhong, et al. Development of 40% prothioconazole·tebuconazole suspension concentrate [J]. World Pesticides, 2022, 44(1): 4." records that the formula of 40% prothioconazole·tebuconazole suspension concentrate is 20% prothioconazole, 20% tebuconazole, 2% CF20S, 2% A788, 1% T-80, 1% 1020P, 0.1% xanthan gum, 1% magnesium aluminum silicate, 3% propylene glycol, 0.5% defoamer 1404, 0.2% citric acid, 0.1% kason, and distilled water to make up 100%. After cold and hot storage, the formula has qualified stability and pourability, the medium particle size is about 1.5μm, which meets the particle size requirements of the suspension concentrate (0.5-5μm), the particle distribution is concentrated, and all indicators are qualified. The processing technology is that the mass of 1.2mm zirconium beads is 1.5 times the mass of the medicine, and the grinding time is 2h.
[0003] The above technical formula is only suitable for triclinic prothioconazole original medicine, while for 40% prothioconazole·tebuconazole suspension prepared from prothioconazole original medicine containing both monoclinic and triclinic crystals, heat storage will cause crystal swelling and bottoming of the system. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a prothioconazole-tebuconazole suspension and a preparation method and application thereof, which has good stability and effect of preventing and controlling wheat fusarium head blight.
[0005] In order to achieve the above object, the present invention provides the following technical solutions:
[0006] The present invention provides a prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0007] Prothioconazole 20%, tebuconazole 20%, wetting dispersant 6-10%, urea 4%, defoamer 0.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up to 100%.
[0008] Preferably, the wetting and dispersing agent includes 7023A and C785;
[0009] The mass ratio of the 7023A to C785 is 3:3-7.
[0010] Preferably, the defoaming agent includes defoaming agent 1501.
[0011] The present invention also provides a method for preparing the prothioconazole-tebuconazole suspension according to the above technical solution, comprising the following steps:
[0012] 1) mixing and shearing the water and the wetting dispersant to obtain a shear material;
[0013] 2) mixing the sheared material obtained in step 1) with a defoamer, a kason and urea to obtain a mixed material;
[0014] The amount of the defoamer is 50% of the total defoamer mass;
[0015] 3) mixing the mixed material obtained in step 2) with prothioconazole, tebuconazole and magnesium aluminum silicate, and then shearing and grinding to obtain a grind;
[0016] 4) The ground material obtained in step 3) is mixed with xanthan gum and the remaining defoamer and then sheared to obtain a 40% prothioconazole-tebuconazole suspension.
[0017] Preferably, the shearing conditions in step 1) include: a time of 20 to 30 minutes and a rotation speed of 1000 to 2000 r / min;
[0018] The temperature of the water is 0-5°C.
[0019] Preferably, the mixing time in step 2) is 20 minutes.
[0020] Preferably, the shearing conditions in step 3) include: a time of 40 to 45 minutes and a rotation speed of 1000 to 2000 r / min.
[0021] Preferably, the grinding conditions in step 3) include: the temperature is lower than 35° C., the grinding time is 1.5 h, and the mass of 1.2 mm zirconium beads is 1.5 times the mass of the prothioconazole-tebuconazole suspension;
[0022] The D of the abrasive 90 Less than 0.5μm.
[0023] Preferably, the shearing conditions in step 4) include: time of 30 min, rotation speed of 1000-2000 r / min.
[0024] The present invention also provides the use of the prothioconazole-tebuconazole suspension described in the above technical solution in preventing and controlling wheat fusarium head blight.
[0025] The beneficial effects of the present invention are:
[0026] 1. Compared with the prior art, the present invention reduces the types of additives, helps save process, is easy to operate, and also improves grinding efficiency, enriching the prior art.
[0027] 2. This technology can maintain good heat storage fluidity and storage stability for prothioconazole technical containing both monoclinic and triclinic crystals.
[0028] During the experiment, three different companies' prothioconazole technical drugs (Anhui Jiuyi Agriculture Co., Ltd., Shandong Hailier Chemical Co., Ltd., Shaoxing Shangyu Xinyinbang Biochemical Co., Ltd.) were used. After 14 days of hot storage, the viscosity was between 450-500 (pa·s), without stratification, water separation, and bottoming. The prothioconazole technical drugs used in the 5 embodiments of the present invention are all from Shaoxing Shangyu Xinyinbang Biochemical Co., Ltd.
[0029] Table 1 Performance of prothioconazole technical
[0030] Prothioconazole TC Helier Jiuyi New Silver State Hot storage (54℃) viscosity (pa·s) 455 480 460 Heat storage (54℃) particle size (μm) 4.8 4.9 4.9 Thermal storage (54℃) water absorption 4% 4% 4%
[0031] 3. The prior art formula is only suitable for the prothioconazole original drug of the triclinic system, and for the 40% prothioconazole·tebuconazole suspension prepared from the prothioconazole original drug containing both the monoclinic system and the triclinic system, heat storage will cause the system to swell and form crystals. The experiments all used the prothioconazole original drug of Xinyinbang and the tebuconazole original drug of Liaoning Zhonghui, and the prior art and the present invention were compared. Examples 1-5 of the present invention all used the prothioconazole original drug of the crystal form 1 containing both the monoclinic system and the triclinic system.
[0032] Table 2 Performance comparison results
[0033] 40% Prothioconazole Tebuconazole SC Prior art The present invention Hot storage (54℃) viscosity (pa·s) 1200 460 Heat storage (54℃) particle size (μm) 17 4.9 Is the heat storage (54℃) bottomed out? yes no
[0034] 4. Prothioconazole inhibits the demethylation of lanosterol, the precursor of sterols in fungi. It is a demethylation inhibitor (DMIs) with good systemic activity, excellent protection, treatment and eradication activity, and a long lasting effect. A large number of field efficacy tests have shown that prothioconazole is not only safe for crops, but also has good disease prevention and treatment effects, and significantly increases yield. Compared with triazole fungicides, prothioconazole has a broader spectrum of fungicidal activity.
[0035] Tebuconazole is a highly effective, broad-spectrum, systemic triazole fungicide with three functions: protection, treatment, and eradication. It has a broad fungicide spectrum and a long duration. Studies have found that tebuconazole, like all triazole fungicides, can inhibit the biosynthesis of ergosterol in fungi.
[0036] Prothioconazole and tebuconazole have the same target, but their modes of action are somewhat different. Studies have shown that prothioconazole has a good inhibitory effect on fusarium spores and has a synergistic effect when combined with tebuconazole. This improves the control effect, expands the sterilization range, reduces the amount of active ingredients, saves drug costs, and reduces environmental pollution. DETAILED DESCRIPTION
[0037] The invention provides a prothioconazole-tebuconazole suspension, which comprises the following components in percentage by weight: 20% of prothioconazole, 20% of tebuconazole, 6-10% of a wetting dispersant, 4% of urea, 0.3% of a defoamer, 0.2% of kason, 1% of magnesium aluminum silicate, 0.1% of xanthan gum, and the content of water is 100%.
[0038] In the present invention, the wetting dispersant preferably includes 7023A and C785. In the present invention, the mass ratio of 7023A to C785 is preferably 3:3-7. In the present invention, the 7023A is provided by Wuxi Yijingfeng Technology Co., Ltd., and the C785 is provided by Wuxi Yijingfeng Technology Co., Ltd. The reasonable combination of the two auxiliary agents 7023A and C785 can adapt to different crystal forms of prothioconazole technical, and the preparation will not flocculate, bottom out and Ostwald ripening after hot storage.
[0039] In the present invention, the defoaming agent preferably includes defoaming agent 1501.
[0040] The present invention also provides a method for preparing the prothioconazole-tebuconazole suspension according to the above technical solution, comprising the following steps:
[0041] 1) mixing and shearing the water and the wetting dispersant to obtain a shear material;
[0042] 2) mixing the sheared material obtained in step 1) with a defoamer, a kason and urea to obtain a mixed material;
[0043] The amount of the defoamer is 50% of the total defoamer mass;
[0044] 3) mixing the mixed material obtained in step 2) with prothioconazole, tebuconazole and magnesium aluminum silicate, and then shearing and grinding to obtain a grind;
[0045] 4) The ground material obtained in step 3) is mixed with xanthan gum and the remaining defoamer and then sheared to obtain a prothioconazole-tebuconazole suspension.
[0046] The present invention mixes and shears the water and the wetting dispersant to obtain a sheared material. In the present invention, the shearing conditions preferably include: a time of 20 to 30 minutes and a rotation speed of 1000 to 2000 r / min. In the present invention, the temperature of the water is preferably 0 to 5°C.
[0047] The present invention mixes the obtained shear material with a defoamer, kason and urea to obtain a mixture; the amount of the defoamer is 50% of the total defoamer mass. In the present invention, the mixing time is preferably 20 minutes.
[0048] The invention mixes the obtained mixed material with prothioconazole, tebuconazole and magnesium aluminum silicate, and then shears and grinds the mixed material to obtain the grind material.
[0049] In the present invention, the shearing conditions preferably include: a time of 40 to 45 minutes, a rotation speed of 1000 to 2000 r / min. In the present invention, the grinding conditions preferably include: a temperature below 35°C, a time of 1.5 hours, and a mass of 1.2 mm zirconium beads of 1.5 times the mass of the prothioconazole tebuconazole suspension. In the present invention, the D of the grinding material is 90 Preferably it is less than 0.5 μm.
[0050] The present invention mixes the obtained grinding material with xanthan gum and the remaining defoamer and then shears to obtain the prothioconazole-tebuconazole suspension. In the present invention, the shearing conditions preferably include: a time of 30 minutes and a rotation speed of 1000-2000 r / min.
[0051] The present invention also provides the use of the prothioconazole-tebuconazole suspension in the above technical solution in preventing and controlling wheat scab. In the present invention, the use method of the prothioconazole-tebuconazole suspension is: wheat: prevention and control object: scab, dosage: 30-50 ml / mu, application method: spraying.
[0052] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0053] Example 1
[0054] A 40% prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0055] Prothioconazole 20%, tebuconazole 20%, 7023A 3%, C785 3%, urea 4%, defoamer 15010.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up 100%.
[0056] Preparation method:
[0057] 1) Mix 7023A and C785 with water at 0-5°C and shear to obtain a sheared material; wherein the shearing conditions are: time 30min, speed 2000r / min;
[0058] 2) mixing the sheared material obtained in step 1) with defoamer 1501, kason and urea to obtain a mixture;
[0059] The amount of defoamer used is 50% of the total defoamer mass, and the mixing is performed at a speed of 2000 r / min for 20 min;
[0060] 3) The mixed material obtained in step 2) is mixed with prothioconazole, tebuconazole, and magnesium aluminum silicate, and then sheared and ground to obtain a grind material. The D of the grind material is90 Less than 0.5 μm; wherein the shearing conditions are: time 40 min, speed 2000 r / min; the grinding conditions are: temperature 30°C, time 1.5 h, the mass of 1.2 mm zirconium beads is 1.5 times the mass of 40% prothioconazole·tebuconazole suspension;
[0061] 4) The ground material obtained in step 3) is mixed with xanthan gum and the remaining defoamer and then sheared to obtain a 40% prothioconazole·tebuconazole suspension concentrate, wherein the shearing conditions are: time 30 minutes, speed 2000 r / min.
[0062] Example 2
[0063] A 40% prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0064] Prothioconazole 20%, tebuconazole 20%, 7023A 3%, C785 4%, urea 4%, defoamer 15010.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up 100%.
[0065] The preparation method is the same as that of Example 1.
[0066] Example 3
[0067] A 40% prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0068] Prothioconazole 20%, tebuconazole 20%, 7023A 3%, C785 5%, urea 4%, defoamer 15010.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up 100%.
[0069] The preparation method is the same as that of Example 1.
[0070] Example 4
[0071] A 40% prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0072] Prothioconazole 20%, tebuconazole 20%, 7023A 3%, C785 6%, urea 4%, defoamer 15010.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up 100%.
[0073] The preparation method is the same as that of Example 1.
[0074] Example 5
[0075] A 40% prothioconazole-tebuconazole suspension, comprising the following components in percentage by weight:
[0076] Prothioconazole 20%, tebuconazole 20%, 7023A 3%, C785 7%, urea 4%, defoamer 15010.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up 100%.
[0077] The preparation method is the same as Example 1.
[0078] The 40% prothioconazole·tebuconazole suspension prepared in Examples 1 to 5 were tested for initial physical properties, dilution stability and storage stability.
[0079] The experimental conditions for measuring viscosity are: rotor No. 2, 30 r / min, and room temperature 25°C.
[0080] Table 3 Initial physical properties and dilution stability
[0081] Example 1 Example 2 Example 3 Example 4 Example 5 Viscosity (pa·s) 440 450 452 446 443 Particle size (d90) μm 4.3 4.2 4.0 4.0 4.2 pH 6.7 6.9 6.7 6.5 6.9 Foaming property(ml) 10 9 12 10 19 Dispersibility in water good excellent excellent excellent Difference
[0082] Excellent: Most of it disperses automatically after entering water; Good: A small part of it disperses automatically after entering water; Poor: Most of it sinks directly to the bottom after entering water.
[0083] The hot storage condition is 54±2℃, cold storage is 0±2℃, and room temperature is 25℃. The cold storage is 7 days and the room temperature is 14 days. After 14 days of hot storage, cool to room temperature and observe the chromatographic water rate on the bottle.
[0084] Table 4 Storage stability
[0085] Thermal storage viscosity pa·s 420 425 420 610 800 hot 6.2 4.8 4.9 4.9 4.8 Particle size (d90) cold 4.5 4.5 4.5 4.5 4.5 often 4 4.2 4.0 4 4.2 Water separation rate (heat) 8% 4% 4% 4% 4% pH value (hot) 6.8 6.9 6.8 6.8 6.5
[0086] It can be concluded from Tables 3 and 4 that the combination of 3% 7023A and 4% C785 can well control storage stability and economy.
[0087] Example 6
[0088] Using urea instead of propylene glycol as an antifreeze agent added to the formulation system (Example 2) can reduce the viscosity of the formulation and increase the fluidity of the formulation. The viscosity results are shown in Table 5.
[0089] Table 5 Antifreeze viscosity test results
[0090]
[0091] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A prothioconazole-tebuconazole suspension, characterized in that, Includes the following components in percentage by mass: Prothioconazole 20%, tebuconazole 20%, wetting dispersant 6-10%, urea 4%, defoamer 0.3%, kason 0.2%, magnesium aluminum silicate 1%, xanthan gum 0.1%, water to make up to 100%.
2. The prothioconazole-tebuconazole suspension according to claim 1, characterized in that The wetting and dispersing agents include 7023A and C785; The mass ratio of the 7023A to C785 is 3:3-7.
3. The prothioconazole-tebuconazole suspension according to claim 1, characterized in that The defoaming agent includes defoaming agent 1501.
4. A method for preparing the prothioconazole-tebuconazole suspension concentrate according to any one of claims 1 to 3, characterized in that: The following steps are involved: 1) mixing and shearing the water and the wetting dispersant to obtain a shear material; 2) mixing the sheared material obtained in step 1) with a defoamer, a kason and urea to obtain a mixed material; The amount of the defoamer is 50% of the total defoamer mass; 3) mixing the mixed material obtained in step 2) with prothioconazole, tebuconazole and magnesium aluminum silicate, and then shearing and grinding to obtain a grind; 4) The ground material obtained in step 3) is mixed with xanthan gum and the remaining defoamer and then sheared to obtain a 40% prothioconazole-tebuconazole suspension.
5. The preparation method according to claim 4, characterized in that: The shearing conditions in step 1) include: a time of 20 to 30 minutes and a rotation speed of 1000 to 2000 r / min; The temperature of the water is 0-5°C.
6. The preparation method according to claim 4, characterized in that: The mixing time in step 2) is 20 minutes.
7. The preparation method according to claim 4, characterized in that: The shearing conditions in step 3) include: a shearing time of 40 to 45 minutes and a rotation speed of 1000 to 2000 r / min.
8. The preparation method according to claim 4, characterized in that: The grinding conditions of step 3) include: the temperature is lower than 35° C., the grinding time is 1.5 h, and the mass of 1.2 mm zirconium beads is 1.5 times the mass of the prothioconazole tebuconazole suspension; The D of the abrasive 90 Less than 0.5μm.
9. The preparation method according to claim 4, characterized in that: The shearing conditions in step 4) include: a shearing time of 30 minutes and a rotation speed of 1000 to 2000 r / min.
10. Use of the prothioconazole-tebuconazole suspension concentrate according to any one of claims 1 to 3 in preventing and controlling wheat fusarium head blight.
